Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk faces US Senate committee
Novo Nordisk CEO faces US Congress scrutiny over weight-loss drug pricing
U.S. Senator Bernie Sanders is set to question Novo Nordisk CEO Lars Jorgensen on Tuesday over the drugmaker's prices for its popular weight-loss and diabetes medicines that can cost Americans more than $1,
Novo Nordisk Stock Slips as CEO Faces Senate Inquiry Into Wegovy, Ozempic Prices
Key Takeaways Novo Nordisk CEO Lars Fruergaard Jorgensen will testify Tuesday before a Senate panel looking into the drug maker's pricing of weight-loss drugs Wegovy and Ozempic.The committee accused the company of charging "outrageously high prices" for the treatments.
Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday
Novo Nordisk CEO Lars Fruergaard Jørgensen faces a Senate hearing led by Bernie Sanders over the high cost of Ozempic and Wegovy, as U.S. lawmakers push for drug price reductions.
20m
Hitting the Pharmaceutical Jackpot With Novo’s Ozempic and Wegovy
Hi, it’s Bob in New York. I’ve been writing about drug costs for years, and Ozempic and Wegovy turn out to be in a unique ...
23h
Ozempic and Wegovy Sales Will Soon Pay for $68 Billion of Novo R&D
Ozempic and Wegovy are making so much money for Novo Nordisk A/S that their cumulative sales will soon surpass the ...
12d
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial
Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...
14h
on MSN
$50 Billion in Sales Make Ozempic and Wegovy Prices Tougher to Justify
Ozempic and Wegovy are making so much money for Novo Nordisk A/S that their cumulative sales will soon surpass the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback